Related Experiment Videos
Itraconazole in tinea versicolor: a review
1Department of Dermatology, Clinic Cesar De Paepe, Brussels, Belgium.
Journal of the American Academy of Dermatology
|September 1, 1990
Summary
Itraconazole effectively treats pityriasis versicolor, a fungal skin infection. This oral antifungal medication, taken at 1000 mg total dose, shows superior results compared to placebo and is well-tolerated.
Area of Science:
- Mycology
- Dermatology
- Pharmacology
Background:
- Pityriasis versicolor is a mild fungal skin disease.
- Orally active triazole antifungals offer a treatment option.
- Itraconazole is a newly developed triazole antifungal agent.
Purpose of the Study:
- To evaluate the efficacy and tolerability of itraconazole in patients with pityriasis versicolor.
- To compare itraconazole with placebo and other antifungal treatments.
Main Methods:
- Patients with pityriasis versicolor were treated with itraconazole.
- A total dose of 1000 mg was administered, typically as 200 mg daily for 5 or 7 days.
- Clinical and mycological assessments were performed 3-4 weeks post-treatment.
Main Results:
- Itraconazole demonstrated effectiveness in treating pityriasis versicolor.
- It was found to be superior to placebo.
- Efficacy was comparable to selenium sulfide, clotrimazole, and ciclopirox olamine.
- Itraconazole exhibited better patient tolerability than selenium sulfide.
Conclusions:
- Itraconazole is an effective and well-tolerated oral treatment for pityriasis versicolor.
- It represents a valuable therapeutic option for this superficial fungal infection.
- Further assessment confirms its role in managing pityriasis versicolor.